Nan Fung Group Holdings Ltd Has $3.90 Million Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)

Nan Fung Group Holdings Ltd lifted its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 11.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 321,746 shares of the company's stock after acquiring an additional 33,900 shares during the quarter. Replimune Group makes up approximately 3.3% of Nan Fung Group Holdings Ltd's holdings, making the stock its 12th largest holding. Nan Fung Group Holdings Ltd owned about 0.47% of Replimune Group worth $3,896,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Sterling Capital Management LLC grew its stake in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after purchasing an additional 1,655 shares during the last quarter. Aster Capital Management DIFC Ltd increased its stake in shares of Replimune Group by 8,798.9% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after buying an additional 8,183 shares during the period. XTX Topco Ltd bought a new stake in shares of Replimune Group during the fourth quarter worth $137,000. Sei Investments Co. acquired a new position in shares of Replimune Group during the fourth quarter valued at $148,000. Finally, KLP Kapitalforvaltning AS bought a new position in Replimune Group in the fourth quarter valued at about $150,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Stock Up 0.8 %

Shares of NASDAQ:REPL traded up $0.08 during midday trading on Thursday, reaching $8.91. 200,241 shares of the company were exchanged, compared to its average volume of 866,428. The firm has a market cap of $685.82 million, a PE ratio of -2.90 and a beta of 1.26. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The stock has a fifty day simple moving average of $10.44 and a two-hundred day simple moving average of $11.69.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). As a group, sell-side analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Analyst Ratings Changes

REPL has been the subject of several recent research reports. BMO Capital Markets boosted their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. JPMorgan Chase & Co. raised their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, HC Wainwright boosted their target price on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $19.43.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.